EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING
|
|
- Pamela Goodwin
- 5 years ago
- Views:
Transcription
1 EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING Commentary provided by: Julie Hall, MHS, MT (ASCP) Assistant Dean, College of Health Professions Assistant Professor, Medical Laboratory Science Grand Valley State University Grand Rapids, MI Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits, click on Earn CE Credits under Continuing Education on the left side of the screen. Learning Outcomes On completion of this exercise, the participant should be able to: describe the use of vancomycin; identify the trough serum vancomycin reference range for patients with nonsevere infection; identify the trough serum vancomycin reference range for patients with severe, invasive infections; explain the appropriate time to measure trough serum vancomycin levels; and discuss the adverse effects associated with vancomycin toxicity. Introduction Most antimicrobial drugs have established dosing regimens that provide for their safe and effective use without requiring laboratory monitoring. For some, however, there is a narrow range between the therapeutic and toxic concentrations, and these require therapeutic drug monitoring to ensure efficacy, prevent toxic effects, and reduce the emergence of resistant strains of microbial pathogens. Vancomycin (vancomycin hydrochloride) is one such antimicrobial drug that has garnered a great deal of attention over the past decade. Debate has ensued over the use of serum vancomycin concentrations to measure clinical effectiveness and prevent drug-induced toxic effects, and about the appropriate therapeutic ranges for serum vancomycin concentrations. Use In the early 1950s, a chemist at Eli Lilly and Company set out to develop antibiotics to treat penicillinresistant staphylococci. Bacteria isolated from the soil in Indonesia, Streptomyces orientalis, produced a substance that proved promising to their efforts and led to the creation of vancomycin, a glycopeptide antibiotic. Vancomycin was approved by the Food and Drug Administration and became commercially available in This antibiotic exhibits time-dependent killing, as opposed to concentration-dependent killing, of gram-positive bacteria by inhibiting the formation of the bacterial cell wall and damaging the cell membrane. Use of early formulations was limited due to associated toxic effects and the arrival of the first semisynthetic penicillins - methicillin sodium, oxacillin sodium, and nafcillin sodium - at approximately the same time. However, the 1980s saw a resurgence in vancomycin use owing to the emergence of American Proficiency Institute nd Test Event 1
2 penicillinase-producing methicillin-resistant Staphylococcus aureus (MRSA) infections and pseudomembranous enterocolitis. 2 Vancomycin s proven effectiveness against penicillin-resistant staphylococci and clostridia make it a valuable alternative to penicillin for the treatment of patients with penicillin allergies, an effective tool in the treatment of patients with MRSA infections, and a successful treatment option for pseudomembranous enterocolitis. Although it is primarily given intravenously for the treatment of invasive gram-positive organisms due to its poor absorption by the gastrointestinal tract, it is ideal for treatment of pseudomembranous enterocolitis when taken orally. The main route of excretion of vancomycin is primarily the kidneys, making renal function an important factor in establishing a dosing regimen. Dosing for maintenance of therapeutic levels can be difficult and is usually based on established nomograms or algorithms that take into account the severity and site of the infection, body weight, renal function as determined by creatinine clearance, and trough serum vancomycin concentration. 3 Therapeutic Ranges Owing to vancomycin s time-dependent rather than concentration-dependent killing, approximately 6-hour half-life, and subsequent long distribution phase, trough serum vancomycin concentrations are more reliable than peak vancomycin concentrations for measuring drug efficacy. There is significant variability in peak concentrations among patients and there is no evidence to support a correlation between peak vancomycin concentrations and efficacy or toxicity. 4 There is often confusion when evaluating vancomycin for therapeutic effectiveness and toxic effects because two different therapeutic ranges are recommended for trough serum vancomycin concentrations, depending on the severity of the infection. For patients with nonsevere infections, such as infections of the skin, soft tissue, or urinary tract, trough serum concentrations should be maintained between 10 and 15 µg/ml. For improved penetration and improved clinical outcome in severe infections such as sepsis, central nervous system infections, bacteremia, hospital-acquired pneumonia, osteomyelitis, and endocarditis, trough serum concentrations should be maintained between 15 and 20 µg/ml. 5 Subtherapeutic levels (less than 10 µg/ml) should be avoided because they have been shown to result in treatment failure and the potential for the development of resistant strains of organisms. 4 Timing of Blood Draws The best predictor of good clinical outcomes for patients undergoing treatment with vancomycin is the ratio of the area under the serum drug concentration time curve to the minimum inhibitory concentration (AUC/MIC) due to large variability in vancomycin pharmacokinetics among patients. Although AUC/MIC ratios of 400 or greater are optimal to achieve clinical effectiveness for the treatment of S aureus infections with an MIC less than 1 mg/l, it is often difficult to obtain multiple serum vancomycin American Proficiency Institute nd Test Event 2
3 concentrations to determine the AUC. Trough serum vancomycin concentrations are considered an alternative to AUC and are recommended as the most accurate and practical method for monitoring vancomycin effectiveness and guiding dosage adjustments. 6 For patients with stable renal function, trough serum vancomycin concentrations should be measured immediately before administration of the fourth dose, at steady state. After the initial steady-state trough vancomycin concentration, routinely monitoring trough vancomycin concentrations in patients undergoing a lower-intensity dosing regimen for fewer than 3 days is not necessary as long as there is no evidence of renal dysfunction. For patients with unstable renal function, dosing intervals are established based on spot serum concentrations until renal function is stable. Spot concentration timing is based on the rate and direction of change in the serum creatinine concentration (renal function). Serum creatinine and trough serum vancomycin concentrations should be monitored at least weekly for patients taking vancomycin for more than 5 days, with a target trough of 15 to 20 µg/ml. This group includes patients with invasive infections, those with renal dysfunction, those who are morbidly obese, those who are critically ill, and those concurrently treated with nephrotoxic medications. 5 Dosage Adjustments Dosage adjustments should be guided by trough levels. Patients with trough serum vancomycin concentrations less than 10 µg/ml should have their dosage adjusted by increasing the total daily dose and not changing the dosing interval. For patients with trough concentrations more than 5 µg/ml above the therapeutic range, subsequent doses should be withheld and vancomycin levels should be monitored daily until trough concentrations are in the therapeutic range. Once in the recommended therapeutic range, a new dosing regimen should be initiated. For patients with trough levels above their recommended therapeutic range by 5 µg/ml or less, a new dosing regimen should be established and implemented at the next scheduled dose. After the fourth dose, at steady state, trough serum vancomycin concentration should be measured to confirm that the dosage adjustment has brought the level to the therapeutic range. 5 Toxic Effects Early preparations of vancomycin were nicknamed Mississippi Mud for their brown color from impurities. A number of adverse effects were associated with those early preparations, including ototoxicity and nephrotoxicity. To this day, many of the adverse effects attributed to the drug originated from the impurities associated with preparations used before the 1980s. 7 Although there is still much debate on the toxic effects associated with vancomycin, recent studies have shown that toxic effects are infrequent with vancomycin monotherapy at typical dosing protocols. Toxic effects are more likely with vancomycin administration in patients with renal insufficiency, those receiving vancomycin concurrently with other American Proficiency Institute nd Test Event 3
4 nephrotoxic or ototoxic drugs, or administration at high doses for prolonged periods. 2 To date, there is little data to support toxicity-associated adverse effects with specific serum concentrations. 4 More frequently, patients experience an infusion-related response, manifesting in what is known as red man syndrome. This histamine-like response produces tingling and flushing of the upper body during or immediately after infusion and has been attributed to rapid infusion of large doses of the antibiotic. Red man syndrome is unrelated to serum vancomycin concentration and is short-lived, usually diminishing after the infusion is completed. 2 Summary After more than 50 years, vancomycin continues to be one of the most widely used antibiotics in the treatment of serious gram-positive infections. The use of serum trough concentrations at recommended levels is essential to monitor clinical effectiveness and make necessary dosage adjustments, keeping in mind that recommended target trough ranges vary depending on the site and severity of the infection. Maintaining the appropriate serum trough ranges will improve clinical outcomes and help to reduce the emergence of resistant strains of pathogens. Despite early reports of associated toxic effects, evidence shows that toxic effects are rare when vancomycin is used in the absence of other nephrotoxic or ototoxic agents. Although there are a number of medications for the treatment of invasive, resistant gram-positive infections, vancomycin continues to be a clinically effective and cost-efficient option. References 1. Levine DP. Vancomycin: a history. Clin Infect Dis. 2006;42(1):S5-S Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1): Hisham M, Zogheib M, Homoud A, Al-Tawfiq JA. Safety and outcome of pharmacy-led vancomycin dosing and monitoring. Chemotherapy. 2015;6(1): Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC Jr, Craig WA. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49(3): Drew RH, Sakoulas G. Vancomycin: parenteral dosing, monitoring, and adverse effects in adults. In: Hooper DC, Baron EL, eds. UptoDate. Waltham, MA: Wolters Kluwer; Accessed December 20, American Proficiency Institute nd Test Event 4
5 6. Ayazkhoo L, Mousavi S, Ramazani F, Ayatollahi-Tafti M, Sa'dabadi Z. Vancomycin utilization evaluation: are we dosing appropriately? J Pharm Care. 2013;1(4): Avent ML, Vaska VL, Rogers BA, Cheng AC, van Hal SJ. Vancomycin therapeutics and monitoring: a contemporary approach. Intern Med J. 2013;43(2): ASCP 2018 American Proficiency Institute nd Test Event 5
Full title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control
Full title of guideline Author: Contact Name and Job Title Division and specialty Scope Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) Changes
More informationVANCOMYCIN DOSING AND MONITORING GUIDELINES
VANCOMYCIN DOSING AND MONITORING GUIDELINES NB Provincial Health Authorities Anti-Infective Stewardship Committee Approved: May 2017 GENERAL COMMENTS Vancomycin is a glycopeptide antibiotic with bactericidal
More informationD DAVID PUBLISHING. Evaluation of the Effectiveness of a Vancomycin Nomogram at Predicting Trough Levels within a Therapeutic Range. 1.
Journal of Pharmacy and Pharmacology 2 (2014) 713-721 doi: 10.17265/2328-2150/2014.12.004 D DAVID PUBLISHING Evaluation of the Effectiveness of a Vancomycin Nomogram at Predicting Trough Levels within
More informationINTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS
Title of guideline (must include the word Guideline (not protocol, policy, procedure etc) INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS Author: Contact Name and Job Title
More informationChallenges in Therapeutic Drug Monitoring:
Challenges in Therapeutic Drug Monitoring: Focus on Vancomycin Pharmacodynamics and Pharmacokinetics Katherine Gallaga, PharmD PGY1 Pharmacy Practice Resident CHRISTUS Spohn Health System 1 Pharmacist
More informationEvaluation of Vancomycin Continuous Infusion in Trauma Patients
OBJECTIVES Evaluation of Vancomycin Continuous Infusion in Trauma Patients Brittany D. Bissell, Pharm.D. PGY-2 Critical Care Pharmacy Resident Jackson Memorial Hospital Miami, Florida Evaluate the potential
More informationD DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2
Journal of Pharmacy and Pharmacology 5 (2017) 607-615 doi: 10.17265/2328-2150/2017.09.001 D DAVID PUBLISHING Comparative Evaluation of Pharmacist-Managed Vancomycin Dosing in a Community Hospital Following
More informationVancomycin Drug Class 1
Drug Class 1 Antibiotic glycopeptide Spectrum 1 Cross Sensitivities / Allergies 1 Refer to product monograph for complete spectrum Gram positive pathogens (e.g., S. aureus, Enterococcus, S. viridans, methicillinresistant
More informationASHP Therapeutic Position Statements 623
ASHP Therapeutic Position Statements 623 Therapeutic Monitoring of Vancomycin in Adult Patients: A Consensus Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society
More informationClinical Guidelines for Use of Antibiotics. VANCOMYCIN (Adult)
VANCOMYCIN (Adult) Please always prescribe VANCOMYCIN in the Variable Dose Antibiotic section of the EPMA SUPPLEMENTARY drug chart (and add a placeholder on the electronic drug chart). 1 Background Vancomycin
More informationTrust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults
A clinical guideline recommended for use: In: By: For: Division responsible for document: Key words: Names of document authors: Job titles of document authors: Name of document author s Line Manager: Job
More informationPolicy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing
ProMedica Health System Clinical Interdepartmental Policy and Procedure: Section: Policy: Date: Subject: Pharmacy Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing
More informationClinical Safety & Effectiveness Cohort # 10
1 Clinical Safety & Effectiveness Cohort # 10 Improving Weight-Based Vancomycin Dosing and Monitoring DATE Educating for Quality Improvement & Patient Safety 2 Financial Disclosure lizabeth A. Walter,
More informationAssessment of Therapeutic Drug Monitoring of Vancomycin in Elderly Patients According to New Guidelines
Original Article Clinical Chemistry Ann Lab Med 2014;34:1-6 http://dx.doi.org/10.3343/alm.2014.34.1.1 ISSN 2234-3806 eissn 2234-3814 Assessment of Therapeutic Drug Monitoring of Vancomycin in Elderly Patients
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationBSWH Pharmacist Continuing Education PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin
BSWH Pharmacist Continuing Education 2015 PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin Objectives Define basic pharmacodynamic and pharmacokinetic principles Describe
More information(Max 2 g) = to nearest 250 mg
Appendix 1 (part 1 of 8): Rubric for competency assessment of pharmacists prescribing and managing vancomycin Empiric Dosing Phase Pts Yes No Data Error OP Did the pharmacist document the indication 2
More informationClinical Study Prospective Trial of a Novel Nomogram to Achieve Updated Vancomycin Trough Concentrations
Interdisciplinary Perspectives on Infectious Diseases Volume 2013, Article ID 839456, 8 pages http://dx.doi.org/10.1155/2013/839456 Clinical Study Prospective Trial of a Novel Nomogram to Achieve Updated
More informationprophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures
1 Glycopeptides appropriate uses serious infections due to beta-lactam- resistant gram-positive microorganisms infections due to gram-positive microorganisms in patients with serious allergy to beta-lactam
More informationVancomycin Pharmacokinetics. Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy
Vancomycin Pharmacokinetics Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy Goals Review the PK properties of vancomycin Compare and contrast methods of dosage regimen design for vancomycin
More informationCubicin A Guide to Dosing
Cubicin A Guide to Dosing Cubicin (Daptomycin) powder for solution for injection or infusion Indications (see SmPC) 1 : Cubicin is indicated for the treatment of the following infections (see sections
More informationIV Vancomycin dosing and monitoring Antibiotic Guidelines. Contents. Intro
IV Vancomycin dosing and Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): as above Authors Division: DCSS & Tertiary Medicine Unique
More informationTHERAPEUTIC MONITORING OF VANCOMYCIN IN CLINICAL PRACTICE
THERAPEUTIC MONITORING OF VANCOMYCIN IN CLINICAL PRACTICE Hana Suchánková, Martina Machačová, Tereza Herodesová Department of Pharmacology, University Hospital Olomouc Introduction and objective: Routine
More informationDevelopment of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s
Beta-lactam antibiotics - Cephalosporins Development of C sporins Targets - PBP s Activity - Cidal - growing organisms (like the penicillins) Principles of action - Affinity for PBP s Permeability properties
More informationEvaluation of Vancomycin Dosing and Corresponding Drug Concentrations in Pediatric Patients
RESEARCH ARTICLE Evaluation of Vancomycin Dosing and Corresponding Drug Concentrations in Pediatric Patients abstract OBJECTIVE: To describe the relationships between dosing strategy, age, and vancomycin
More informationCLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel
CLINICAL USE OF GLYCOPEPTIDES Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel Glycopeptides Natural Vancomycin introduced in 1958 Teicoplanin introduced in Europe
More informationIMPROVING VANCOMYCIN DOSING AND MONITORING IN THE ABSENCE OF A FORMAL PHARMACOKINETIC SERVICE:
IMPROVING VANCOMYCIN DOSING AND MONITORING IN THE ABSENCE OF A FORMAL PHARMACOKINETIC SERVICE: IMPACT OF A PHARMACY DEPARTMENT-WIDE APPROACH IN A COMMUNITY HOSPITAL SETTING November 2014 Monica Dorobisz,
More informationVancomycin: Class: Antibiotic.
Vancomycin: Class: Antibiotic. Indications: Treatment of patients with infections caused by staphylococcal species and streptococcal Species. Available dosage form in the hospital: 1G VIAL, 500MG VIAL.
More informationAminoglycosides John A. Bosso, Pharm.D.
AMINOGLYCOSIDES Therapeutics/PHRMP-73 Aminoglycoside Mechanism of Action Aminoglycosides bind to 30s ribosomal subunit resulting in mistranslation of mrna thus disrupting protein synthesis. They are rapidly
More informationJoint Trust Guideline for the Use of Intravenous Vancomycin in Paediatrics
A clinical guideline recommended For use in: All clinical areas where vancomycin is prescribed for Children aged 1 month to 16 years By: All medical, nursing, pharmacy, microbiology and phlebotomy paediatric
More informationORIGINAL ARTICLE DOI: (e) ISSN Online: (p) ISSN Print: Anand Kumar Singh 1, Poonam Verma 2. Sciences, Dehradun
ORIGINAL ARTICLE CLINICAL ASSESSMENT OF NEPHROTOXICITY ASSOCIATED WITH VANCOMYCIN TROUGH CONCENTRATIONS DURING TREATMENT OF DEEP-SEATED INFECTIONS: A RETROSPECTIVE ANALYSIS Anand Kumar Singh 1, Poonam
More informationSBUH Aminoglycoside Dosing Protocol
Adult Aminoglycoside Dosing for Gram negative infections prior to available serum levels (Excludes patients with cystic fibrosis, OB GYN patients and surgical prophylaxis) Cr Cl 40 ml/min 5 7 mg/kg INT
More informationthe American Society of Health-System Pharmacists, the Infectious Diseases Society of
1 2 3 4 Therapeutic monitoring of vancomycin: A revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious
More informationPHA5128 Dose Optimization II Case Study 3 Spring 2013
Use the vancomycin dosing nomogram table below: A female patient, 57 years of age, 5 6 in height and 100 in weight had an infection requiring vancomycin treatment. Her serum creatinine was 0.8 mg/d. What
More informationVANLID Capsules (Vancomycin hydrochloride)
Published on: 22 Sep 2014 VANLID Capsules (Vancomycin hydrochloride) Composition VANLID Capsules Each capsule contains: Vancomycin Hydrochloride IP equivalent to Vancomycin.. 250 mg Approved colours used
More information(telavancin) Healthcare Professional s Guide. Version 2, 4 November 2014
VIBATIV (telavancin) Healthcare Professional s Guide Version 2, 4 November 2014 1 Table of Contents Introduction... 3 About Vibativ / Therapeutic indications... 3 Antimicrobial spectrum of activity for
More informationNHS Grampian Staff Guidance for the Administration of Intravenous Vancomycin in Adults via Intermittent (pulsed) Infusion
Acute Sector NHS Grampian Staff Guidance for the Administration of Intravenous Vancomycin in Adults via Intermittent (pulsed) Infusion Co-ordinators: Gillian Macartney Fiona McDonald Specialist Antibiotic
More informationEDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE
EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click
More informationTDM of Aminoglycoside Antibiotics
TDM Lecture 3 5 th Stage TDM of Aminoglycoside Antibiotics The aminoglycoside antibiotics are widely used for the treatment of gram-negative infections, often in combination with a β-lactam antibiotic
More informationUse ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:
Amikacin is a partially restricted (amber) antibiotic for the treatment of infections due to gentamicin resistant Gram negative bacilli or as advised by microbiology. As with other aminoglycosides, therapeutic
More informationAdult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016
Adult Inpatient Antibiogram Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates January to December 2016 Department of Pathology Camille Hamula, PhD Director, Clinical Microbiology
More informationESCMID Online Lecture Library. by author
Hospital Universitario Virgen Macarena, Seville New drugs against MRSA and VRE L. Eduardo López Cortés Seville, 8th July Tedizolid Oxazolidinone Ceftaroline // Ceftobiprole 5 th gen cephalosporin Overview
More informationVANCOCIN CAPSULES (vancomycin hydrochloride)
PRODUCT INFORMATION VANCOCIN CAPSULES (vancomycin hydrochloride) This preparation for the treatment of colitis is for oral use only. Vancocin must be given orally for treatment of staphylococcal enterocolitis
More informationZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN
ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN Anne Smits Fellow neonatologie UZ Leuven Use of antibiotics in neonates 50 European hospitals 23 non-european hospitals Countries n = 14 n = 9 Pediatric
More informationGuidelines for Monitoring of Vancomycin Serum Concentrations in Adult Patients
Guidelines for Monitoring of Vancomycin Serum Concentrations in Adult Patients Guidelines developed by UWHC Department of Pharmacy Author: Cindy Gaston, RPh, PharmD Reviewed by: Antimicrobial Subcommittee,
More informationTDM. Measurement techniques used to determine cyclosporine level include:
TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.
More informationInfections Amenable to OPAT. (Nabin Shrestha + Ajay Mathur)
3 Infections Amenable to OPAT (Nabin Shrestha + Ajay Mathur) Decisions regarding outpatient treatment of infections vary with the institution, the prescribing physician, the individual patient s condition
More informationPharmacokinetics of daptomycin in a patient with severe renal failure not under dialysis
AAC Accepts, published online ahead of print on 1 April 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00230-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Pharmacokinetics
More informationClinical Study Achievement of Vancomycin Therapeutic Goals in Critically Ill Patients: Early Individualization May Be Beneficial
Critical Care Research and Practice Volume 2016, Article ID 1245815, 7 pages http://dx.doi.org/10.1155/2016/1245815 Clinical Study Achievement of Vancomycin Therapeutic Goals in Critically Ill Patients:
More informationVancomycin-associated nephrotoxicity, a case control study
Master Thesis in Medicine, Nr 859 Vancomycin-associated nephrotoxicity, a case control study Student Tutor Pr. Thierry Buclin, PD MER Div. of Clinical Pharmacology, CHUV Co-tutor Nicolas Widmer Div. of
More informationMethicillin-Resistant Staphylococcus aureus (MRSA) S urveillance Report 2008 Background Methods
Methicillin-Resistant Staphylococcus aureus (MRSA) Surveillance Report 2008 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services
More informationPharmacist and Physician Collaborative Practice Model Improves Vancomycin Dosing in an Intensive Care Unit
International Journal of Clinical Medicine, 2016, 7, 675-684 http://www.scirp.org/journal/ijcm ISSN Online: 2158-2882 ISSN Print: 2158-284X Pharmacist and Physician Collaborative Practice Model Improves
More informationAdult Institutional Pharmacokinetics Protocol
Adult Institutional Pharmacokinetics Protocol Policy Title: Clinical Pharmacokinetics (PK) Service Policy Policy Statement: It is the policy of UMHC that PK consult orders (for vancomycin or aminoglycosides)
More informationNephrotoxicity. Pros and Cons of the article: Relationship between Initial Vancomycin
Pros and Cons of the article: Relationship between Initial Vancomycin Nephrotoxicity among Hospitalized Patients Diane M. Cappelletty, Pharm.D. Associate Professor Pharmacy Practice The University of Toledo
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 October 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 October 2006 CUBICIN 350 mg (daptomycin), powder for perfusion solution Box of 1 bottle (CIP code: 567 219-3) CUBICIN
More informationLessons from recent studies. João Gonçalves Pereira UCIP DALI
Lessons from recent studies João Gonçalves Pereira UCIP DALI 1 Patterns of Antimicrobial Activity Concentration C max Aminoglycosides Cmax/MIC>10 Metronidazol Area under the concentration curve Azithromycin
More informationPublic Assessment Report Scientific discussion. Vancomycin Farmaplus Vancomycin hydrochloride SE/H/1158/01-02/MR
Public Assessment Report Scientific discussion Vancomycin Farmaplus Vancomycin hydrochloride SE/H/1158/01-02/MR This module reflects the scientific discussion for the approval of Vancomycin Farmaplus 500
More informationAMINOGLYCOSIDES DOSING AND MONITORING GUIDELINES
Approved: September 2017 AMINOGLYCOSIDES DOSING AND MONITORING GUIDELINES NB Provincial Health Authorities Anti-Infective Stewardship Committee GENERAL COMMENTS Aminoglycosides (AG) include gentamicin,
More informationVancomycin Orion , Version 2 Public Summary of the Risk Management Plan
Vancomycin Orion 18.1.2016, Version 2 Public Summary of the Risk Management Plan VI.2 Elements for a Public Summary Vancomycin Orion is intravenously administered glycopeptide antibiotic. It is indicated
More informationVancomycin dosing in morbidly obese patients
Eur J Clin Pharmacol (1998) 54: 621±625 Ó Springer-Verlag 1998 PHARMACOKINETICS AND DISPOSITION L. A. Bauer á D. J. Black á J. S. Lill Vancomycin dosing in morbidly obese patients Received: 9 March 1998
More informationMRSA Micro Scan Pos Combo 6J DADE BEHRING VCM
PKPD MRSA 1 1 2 1 1 2 17 1 26 17 3 16 vancomycinvcm methicillin-resistant Staphylococcus aureusmrsa 31 pharmacokineticpkparameter retrospective VCM 21 10 PK parameter Mann- Whitney U-test Cmax 37.1 µ gml29.942
More informationGhada Elba et al. Int. Res. J. Pharm. 2016, 7 (11) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Research Article DESIGNING A FEASIBLE METHOD TO PREDICT VANCOMYCIN TROUGH LEVELS IN PEDIATRIC POPULATION USING PATIENTS PARAMETERS
More informationPHA5128 Dose Optimization II Case Study I Spring 2013
Silsamicin is an investigational compound being evaluated for its antimicrobial effect. The route of administration for this drug is via intravenous bolus. Approximately 99.9% of this drug is eliminated
More informationTherapeutic Dose Monitoring for Linezolid in a Patient with MRSA Pneumonia with Bacteremia in Diabetes Insipidus
Infect Dis Ther (2016) 5:81 87 DOI 10.1007/s40121-015-0100-z CASE REPORT Therapeutic Dose Monitoring for Linezolid in a Patient with MRSA Pneumonia with Bacteremia in Diabetes Insipidus Yoshihiko Nakamura.
More informationOptimized Use of Vancomycin
E-Newsletter #1 Optimized Use of Vancomycin FROM THE EDITOR S DESK Methicillin-resistant Staphylococcus aureus (MRSA) is a serious concern for clinicians managing infectious diseases in the healthcare
More informationSHC Vancomycin Dosing Guide
SHC Vancomycin Dosing Guide A: Initial dosing considerations B. Pharmacodynamic Targets: goal AUC and troughs C. Loading dose D: Initial Vancomycin Maintenance Dosing and Serum Concentration Monitoring
More informationRenal Unit. Catheter Related Bacteraemia Guidelines
Renal Unit Policy Manager Drew Henderson Policy Group Renal Unit Policy Established 21/01/2014 Policy Review Period/Expiry 21/01/2015 Last Updated 21/01/2014 This policy does apply to Medical/Dental Staff
More informationCurve Your Enthusiasm: Using AUC:MIC pharmacokinetics to optimize vancomycin dosing
Curve Your Enthusiasm: Using AUC:MIC pharmacokinetics to optimize vancomycin dosing AKPhA 2019 Ryan W. Stevens, PharmD, BCIDP Infectious Diseases Clinical Pharmacy Specialist Providence Alaska Medical
More informationCAT. Dosisaanpassing van antibiotica, toepasbaarheid van beschikbare calculators. Apr. Glynis Frans Supervisor: Prof. Apr.
CAT Dosisaanpassing van antibiotica, toepasbaarheid van beschikbare calculators Apr. Glynis Frans Supervisor: Prof. Apr. Katrien Lagrou 1. What are the current guidelines and recommendations on TDM for
More informationEVALUATION OF VANCOMYCIN INITIAL DOSING AND THE RESULTANT TROUGH LEVEL IN PAEDIATRIC PATIENTS
Malaysian Journal of Pharmaceutical Sciences Vol. 12, No. 1, 67 77 (2014) EVALUATION OF VANCOMYCIN INITIAL DOSING AND THE RESULTANT TROUGH LEVEL IN PAEDIATRIC PATIENTS LIANG ANN LIM 1, MICHELLE SZE HUI
More informationElevated Vancomycin Trough Concentration: Increased Efficacy and/or Toxicity?
Iranian Journal of Pharmaceutical Research (2014), 13 (4): 1241-1247 Received: June 2013 Accepted: November 2013 Copyright 2014 by School of Pharmacy Shaheed Beheshti University of Medical Sciences and
More informationROSOBAC-1GM / ROSOBAC-FORT
ROSOBAC-1GM / ROSOBAC-FORT ROSOBAC - 1GM. COMPOSITION : Each vial contains Sterile Cefoperazone Sodium IP Eq. to Anhydrous Cefoperazone - Sterile Sulbactam Sodium USP Eq. to Anhydrous Sulbactam - ROSOBAC
More informationVancomycin: A 50-something-yearold antibiotic we still don t understand
Current Drug Therapy CME CREDIT EDUCATIONAL OBJECTIVES: Readers will use vancomycin appropriately Amy Schilling, PharmD Department of Pharmacy, The University of Texas Medical Branch, Galveston Elizabeth
More informationEvaluation of a protocol for vancomycin administration in critically patients with and without kidney dysfunction
Spadaro et al. BMC Anesthesiology (2015) 15:95 DOI 10.1186/s12871-015-0065-1 RESEARCH ARTICLE Open Access Evaluation of a protocol for vancomycin administration in critically patients with and without
More informationAXITAB-CV TAB. COMPOSITION :
AXITAB-CV TAB. COMPOSITION : Each film coated tablet contains: Cefuroxime Axetil I.P. Eq. to Anhydrous 500mg. Potassium Clavulanate Diluted I.P. Eq. to Clavulanic Acid 125mg DESCRIPTION : Cefuroxime Axetil
More informationTHE USE OF THE PENICILLINASE-RESISTANT
Therapeutic problems THE USE OF THE PENICILLINASE-RESISTANT PENICILLIN IN THE PNEUMONIAS OF CHILDREN MARTHA D. Yow, MARY A. SOUTH AND CHARLES G. HESS From the Department of Pediatrics, Baylor University
More informationPHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS
PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS
More informationMesporin TM. Ceftriaxone sodium. Rapid onset, sustained action, for a broad spectrum of infections
Ceftriaxone sodium Rapid onset, sustained action, for a broad spectrum of infections 1, 2, 3 Antibiotic with a broad spectrum of activity Broad spectrum of activity against gram-positive* and gram-negative
More informationMEDICATION MONITORING: Pharmacist-Managed Intravenous (IV) Vancomycin Protocol
I. PURPOSE MEDICATION MONITORING: Pharmacist-Managed Intravenous (IV) Vancomycin Protocol To allow standardized pharmacist management of IV vancomycin in the inpatient setting using evidence-based guidelines
More informationภก.วส นต กาต บ. Use of vancomycin is appropriate or acceptable. FDA Labeled Indication
Quality improvement for DUE: Vancomycin, Linezolid and Daptomycin Vancomycin ภก.วส นต กาต บ Vancomycin. In: DRUGDEX System [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically.
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationAntimicrobial Reference Laboratory
Antimicrobial Reference Laboratory GUIDELINE RANGES FOR TDM 2016-17 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust Southmead Hospital Bristol, BS10 5NB UK Aminoglycosides Gentamicin
More informationOpen Forum Infectious Diseases MAJOR ARTICLE
Open Forum Infectious Diseases MAJOR ARTICLE Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting:
More informationPALO VERDE HEALTH CARE DISTRICT REGULAR BOARD OF DIRECTORS MEETING MINUTES July 27, 2016 City Council Chambers
PVHD BOD Meeting Minutes July 27, 2016 Page 1 of 6 PALO VERDE HEALTH CARE DISTRICT REGULAR BOARD OF DIRECTORS MEETING MINUTES July 27, 2016 City Council Chambers Directors Present Administrative Staff
More informationlife-threatening infections
Vancomycin Vancomycin has become increasingly important in the treatment of life-threatening infections. MRSA infections. Methicillin-resistant Staphylococcus epidermidis (MRSE) infections Enterococcal
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More informationThe association between vancomycin trough concentrations and acute kidney injury in the neonatal intensive care unit
Bhargava et al. BMC Pediatrics (2017) 17:50 DOI 10.1186/s12887-017-0777-0 RESEARCH ARTICLE Open Access The association between vancomycin trough concentrations and acute kidney injury in the neonatal intensive
More informationVancomycin nephrotoxicity: frequency and mechanistic aspects
Vancomycin nephrotoxicity: frequency and mechanistic aspects April 24th 2018 Yosu LUQUE Urgences Néphrologiques et Transplantation rénale Hôpital Tenon, Paris Late 40 s: Penicillin-resistant staphylococcus
More informationAntibiotic Treatment of Adults With Infective Endocarditis Due to Streptococci, Enterococci, Staphylococci, and HACEK Microorganisms
Antibiotic Treatment of Adults With Infective Endocarditis Due to Streptococci, Enterococci, Staphylococci, and HACEK Microorganisms Walter R. Wilson, MD; Adolf W. Karchmer, MD; Adnan S. Dajani, MD; Kathryn
More informationPharmacodynamics: the methods
Pharmacodynamics: the methods In vitro models Animal models Clinical studies Population studies With the support of Wallonie-Bruxelles-International 3B-1 Pharmacodynamics: the methods "un peu de tout "
More informationImpact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review
Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 584 608 doi: 10.1111/jcpt.12200 Review Article Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive
More informationOutpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry
doi: 10.1111/j.1742-1241.2008.01824.x ORIGINAL PAPER Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry W. J. Martone, K. C. Lindfield, D. E. Katz OnlineOpen: This
More informationPHA Spring First Exam. 8 Aminoglycosides (5 points)
PHA 5128 Spring 2012 First Exam 1 Aminoglycosides (5 points) 2 Aminoglycosides (10 points) 3 Basic Principles (5 points) 4 Basic Principles (5 points) 5 Bioavailability (5 points) 6 Vancomycin (5 points)
More informationDaptomycin in Clinical Practice. Paolo Grossi
Clinica delle Malattie Infettive e Tropicali Università degli Studi dell Insubria Ospedale di Circolo e Fondazione Macchi, Varese Second Opinion Infettivologica Centro Nazionale Trapianti, ISS, Roma Daptomycin
More informationAntimicrobial Reference Laboratory
Antimicrobial Reference Laboratory GUIDELINE RANGES FOR TDM 2018 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust Southmead Hospital Bristol, BS10 5NB Guideline Ranges 2018 Aminoglycosides
More informationDepartment of Pharmacy Services, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA; 2
Pathogens 2015, 4, 599-605; doi:10.3390/pathogens4030599 Article OPEN ACCESS pathogens ISSN 2076-0817 www.mdpi.com/journal/pathogens Assessing the Surrogate Susceptibility of Oxacillin and Cefoxitin for
More informationAMINOGLYCOSIDES TDM D O N E B Y
AMINOGLYCOSIDES TDM DONE BY: SARA ALARFAJ 2014 OUTLINE Introduction about Aminoglycosides. Spectrum/uses. TDM Aminoglycosides TDM Pharmacodynamics Pharmacokinetics. Dosing in AG. Sampeling time and Monitoring.
More informationVancomycin Orion , Version 1.0. Public Summary of the Risk Management Plan
Vancomycin Orion 18.6.2015, Version 1.0 Public Summary of the Risk Management Plan VI.2 Elements for a Public Summary Vancomycin Orion is intravenously administered glycopeptide antibiotic. It is indicated
More informationInfective Endocarditis Empirical therapy Antibiotic Guidelines. Contents
Infective Endocarditis Empirical therapy Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Group Additional author(s): as above Authors Division: Division of Clinical
More informationApproved by: SMG Origination Date: 06/14 Expiration Date: 06/17 Review Date: Revision Date: POLICY and PROCEDURE Archived Date: Page 1 of 14
POLICY and PROCEDURE Archived Date: Page 1 of 14 PURPOSE In order to provide consistent and optimal vancomycin and aminoglycoside dosing and monitoring, a pharmacokinetic (PK) service will be provided
More information